Attached files
file | filename |
---|---|
EX-99.2 - INTERLEUKIN GENETICS INC | v201902_ex99-2.htm |
EX-99.1 - INTERLEUKIN GENETICS INC | v201902_ex99-1.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM 8-K
CURRENT
REPORT PURSUANT
TO
SECTION 13 OR 15(D) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date of
report (Date of earliest event reported): November 11,
2010
Interleukin
Genetics, Inc.
(Exact
Name of Registrant as Specified in Its Charter)
Delaware
(State or
Other Jurisdiction of Incorporation)
001-32715
|
94-3123681
|
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
|
135
Beaver Street Waltham, MA
|
02452
|
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
(781)
398-0700
(Registrant’s
Telephone Number, Including Area Code)
(Former
Name or Former Address, if Changed Since Last Report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General
Instruction A.2. below):
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR 240.13e-4(c))
|
ITEM
2.02
|
Results
of Operations and Financial
Condition.
|
On
November 11, 2010, Interleukin Genetics, Inc. issued a press release and
held a conference call to report its financial and operational results for
the third quarter ended September 30, 2010. A copy of the press release is
attached to this Current Report on Form 8-K as Exhibit 99.1 and a copy
of a transcript of portions of the conference call is attached as Exhibit 99.2,
and each is incorporated herein by reference.
The
information in this Current Report on Form 8-K, including Exhibits 99.1 and
99.2, is being furnished and shall not be deemed to be “filed” for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended, or
otherwise subject to the liability of that section, and shall not be
incorporated by reference into any registration statement or other document
filed under the Securities Act of 1933, as amended, or the Exchange Act, except
as shall be expressly set forth by specific reference in such
filing.
Item
9.01
|
Financial
Statements and Exhibits.
|
(d)
|
Exhibits
|
Exhibit
Number
|
Description
|
|
99.1
|
Press
Release dated November 11, 2010.
|
|
99.2 | Transcript of Portions of Conference Call Held on November 11, 2010. |
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Interleukin
Genetics, Inc.
|
||
(Registrant)
|
||
Date:
November 11, 2010
|
/s/
ELIOT M. LURIER
|
|
Eliot
M. Lurier
|
||
Chief
Financial Officer
|
||
(Signature)
|